Download PDF
Thromb Haemost 1983; 50(02): 513-517
DOI: 10.1055/s-0038-1665243
Original Article
Schattauer GmbH Stuttgart

Effect of the Calcium-Entry Blocking Agent Nifedipine on Activation of Human Platelets and Comparison with Verapamil

P Han
The Department of Medicine and Clinical Science, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
,
C Boatwright
The Department of Medicine and Clinical Science, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
,
N G Ardlie
The Department of Medicine and Clinical Science, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
› Author Affiliations
Further Information

Publication History

Received 17 December 1982

Accepted 05 May 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effects of the calcium-entry blocking agent nifedipine on the activation of human platelets by various agonists has been studied and compared with verapamil. Like verapamil, nifedipine inhibited platelet aggregation and secretion caused by collagen, the second phase of ADP-induced aggregation, and aggregation caused by the ionophore A23187. Both agents inhibited the formation of TXB2 from endogenous arachidonate, whereas only nifedipine inhibited platelet aggregation and decreased TXB2 formation caused by exogenous arachidonate without inhibiting uptake. These results indicate that both calcium-blocking agents may be inhibiting the release of arachidonate in platelets by phospholipases, and that nifedipine also inhibits the formation and action of thromboxane A2 in platelets. Epinephrine-induced aggregation was inhibited by low concentrations of verapamil while nifedipine only inhibited aggregation by epinephrine at much higher concentrations. It is suggested that low concentrations of verapamil inhibit epinephrine-induced aggregation by interacting with platelet α-adrenergic receptors, and that higher concentrations of both calcium-blocking agents inhibit platelet responses to other aggregating agents by preventing intracellular calcium mobilization.

Keywords

Platelet activation - Verapamil - Collagen - ADP - Arachidonic acid - A23187 - Calcium
 

  • References

  • 1 Gerrard JM, Peterson DA, White JG. Calcium mobilization. In Platelets in Biology and Pathology -2. Gordon JL. (ed) Research Monographs in Cell and Tissue Pathology Elsevier/North Holland; Amsterdam: 1981. 5 407-436
    Google Scholar
  • 2 Feinstein MB, Rodan GA, Cutler LS. Cyclic AMP and calcium in platelet function. In Platelets in Biology and Pathology -2. Gordon JL. (ed) Research Monographs in Cell and Tissue Pathology Elsevier/ North Holland; Amsterdam: 1981. 5 437-472
    Google Scholar
  • 3 Ardlie NG. Calcium ions, drug action and platelet function. Pharmacol Ther 1982; 18: 249-270
    CrossrefPubMedGoogle Scholar
  • 4 Cohn JN. Calcium-entry blockers in coronary artery disease. Circulation 1982; 65 Suppl (Suppl. 01) 1-2
    CrossrefPubMedGoogle Scholar
  • 5 Vanhoutte PM. Calcium-entry blockers and vascular smooth muscle. Circulation 1982; 65 Suppl (Suppl. 01) 11-19
    PubMedGoogle Scholar
  • 6 Thorens S, Haeusler G. Effects of some vasodilators on calcium translocation in intact and fractionated vascular smooth muscle . Eur J Pharmacol 1979; 54: 79-91
    CrossrefPubMedGoogle Scholar
  • 7 Church J, Zsoter TT. Calcium antagonistic drugs. Mechanisms of action Can J Physiol Pharmacol 1980; 58: 254-264
    CrossrefPubMedGoogle Scholar
  • 8 Owen NE, Feinberg H, LeBreton GC. Epinephrine induces Ca2+ uptake in human blood platelets. Am J Physiol 1980; 239: H483-H488
    PubMedGoogle Scholar
  • 9 Owen NE, LeBreton GC. Ca2+ mobilization in blood platelets as visualized by chloretracycline fluorescence. Am J Physiol 1981; 241: H613-H619
    PubMedGoogle Scholar
  • 10 Ikeda Y, Kikuchi M, Toyama K, Watanabe K, Ando Y. Inhibition of human platelet functions by verapamil. Thromb Haemostas 1981; 45: 158-161
    PubMedGoogle Scholar
  • 11 Madsen NP. Use of toluene/triton X-100 scintillation mixture for counting C14-protein radioactivity. Anal Biochem 1969; 29: 542-544
    CrossrefPubMedGoogle Scholar
  • 12 Cameron HA, Ardlie NG. The facilitating effects of adrenaline on platelet aggregation. Prostagland Leuk Med 1982; 9: 117-128
    CrossrefPubMedGoogle Scholar
  • 13 Brown R, Albano JD M, Ekins RP, Scherzi AM, Tampion W. A simple and sensitive saturation assay method for measurement of adenosine 3’-5’ cyclic monophosphate. Biochem J 1971; 121: 561-562
    CrossrefPubMedGoogle Scholar
  • 14 Cazenave JP, Packham MA, Mustard JF. Adherence of platelets to a collagen-coated surface: development of a quantitative model. J Lab Clin Med 1973; 82: 978-990
    PubMedGoogle Scholar
  • 15 Han P, Boatwright C, Ardlie NG. Inhibition of platelet function by antiarrhythmic drags, verapamil and disopyramide. Thromb Haemostas 1982; 47: 150-153
    PubMedGoogle Scholar
  • 16 O’Rourke MF. Angina pectoris, coronary artery spasm and calcium entry blocking agents. Aust NZ J Med 1982; 12: 465-466
    CrossrefPubMedGoogle Scholar
  • 17 Dargie HJ, Lunch PG, Krikler DM, Harris L, Krikler S. Nifedipine and propranolol: beneficial drag interaction. Am J Med 1981; 71: 676-682
    CrossrefPubMedGoogle Scholar
  • 18 Daly K, Bergman G, Rothman M, Atkinson L, Jackson G, Jewitt DE. Beneficial effects of adding nifedipine to beta adrenergic blocking therapy in angina pectoris. Eur J Cardiol 1982; 3: 42-46
    PubMedGoogle Scholar
  • 19 Feinstein MB. Release of intracellular membrane-bound calcium precedes the onset of stimulus-induced exocytosis in platelets. Biochem Biophys Res Commun 1980; 93: 593-600
    CrossrefPubMedGoogle Scholar
  • 20 Le Breton GC, Dinerstein RJ, Roth LJ, Feinberg H. Direct evidence for intracellular divalent cation redistribution associated with platelet shape change. Biochem Biophys Res Commun 1976; 71: 362-370
    CrossrefPubMedGoogle Scholar
  • 21 Le Breton GC, Sandler WC, Feinberg H. The effects of D2O and Chlortetracycline on ADP-induced platelet shape change and aggregation. Thromb Res 1976; 8: 477-485
    CrossrefPubMedGoogle Scholar
  • 22 Charo IF, Feinman RD, Detwiler TC. Inhibition of platelet secretion by an antagonist of intracellular calcium. Biochem Biophys Res Commun 1976; 72: 1462-1467
    CrossrefPubMedGoogle Scholar
  • 23 Le Breton GC, Dinerstein RJ. Effect of the calcium antagonist TMB- 6 on intracellular calcium redistribution associated with platelet shape change. Thromb Res 1977; 10: 521-523
    CrossrefPubMedGoogle Scholar
  • 24 Massini P, Lüscher EF. On the significance of the influx of calcium ions into stimulated human blood platelets. Biochim Biophys Acta 1976; 436: 652-663
    CrossrefPubMedGoogle Scholar
  • 25 Bamathan ES, Addonizio VP, Shattil SJ. Interaction of verapamil with human platelet α-adrenergic receptors. Am J Physiol 1982; 242: H19-H23
    CrossrefPubMedGoogle Scholar
  • 26 Johnson H. Effects of nifedipine (adalat®) on platelet function in vitro and in vivo. Thromb Res 1981; 21: 523-528
    CrossrefPubMedGoogle Scholar